- Home
- FTDR vs NUVL Comparison
FTDR vs NUVL Comparison
Compare FTDR & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- NUVL
- Stock Information
- Founded
- FTDR 1971
- NUVL 2017
- Country
- FTDR United States
- NUVL United States
- Employees
- FTDR N/A
- NUVL N/A
- Industry
- FTDR Diversified Commercial Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- FTDR Finance
- NUVL Health Care
- Exchange
- FTDR Nasdaq
- NUVL Nasdaq
- Market Cap
- FTDR 4.8B
- NUVL 5.8B
- IPO Year
- FTDR 2018
- NUVL 2021
- Fundamental
- Price
- FTDR $67.14
- NUVL $83.85
- Analyst Decision
- FTDR Hold
- NUVL Strong Buy
- Analyst Count
- FTDR 4
- NUVL 9
- Target Price
- FTDR $59.75
- NUVL $118.89
- AVG Volume (30 Days)
- FTDR 576.1K
- NUVL 395.0K
- Earning Date
- FTDR 11-03-2025
- NUVL 11-11-2025
- Dividend Yield
- FTDR N/A
- NUVL N/A
- EPS Growth
- FTDR 29.61
- NUVL N/A
- EPS
- FTDR 3.36
- NUVL N/A
- Revenue
- FTDR $1,966,000,000.00
- NUVL N/A
- Revenue This Year
- FTDR $14.54
- NUVL N/A
- Revenue Next Year
- FTDR $6.49
- NUVL N/A
- P/E Ratio
- FTDR $20.08
- NUVL N/A
- Revenue Growth
- FTDR 8.62
- NUVL N/A
- 52 Week Low
- FTDR $35.61
- NUVL $55.54
- 52 Week High
- FTDR $69.36
- NUVL $106.32
- Technical
- Relative Strength Index (RSI)
- FTDR 57.76
- NUVL 56.85
- Support Level
- FTDR $66.03
- NUVL $81.02
- Resistance Level
- FTDR $69.36
- NUVL $87.90
- Average True Range (ATR)
- FTDR 1.42
- NUVL 3.72
- MACD
- FTDR -0.16
- NUVL 0.38
- Stochastic Oscillator
- FTDR 45.05
- NUVL 68.14
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.